Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
Top 10 Correlated ETFs
In the News
Best Penny Stocks To Buy? Einhorn, Lynch, Cohen & Dalio Own These 5
Top Wall Street Investors Own These 5 Penny Stocks. Are They A Buy Now?
Legendary Investor Peter Lynch Just Bet on IMAC Stock. 9 Things to Know.
IMAC stock is soaring higher today on news that legendary investor Peter Lynch has taken a stake in little-known IMAC Holdings. The post Legendary Investor Peter Lynch Just Bet on IMAC Stock.
Time to Take Profits on IMAC Stock After Shares Soar on Walmart News
It is time to sell your IMAC stock and make a nice profit on the recent rally because the company hasn't shown the ability to make profits. The post Time to Take Profits on IMAC Stock After Shares Soar on Walmart News appeared first on InvestorPlace.
Best Reddit Penny Stocks To Buy Now? 5 Trending Stocks To Watch Today
What are the best penny stocks to buy today? The post Best Reddit Penny Stocks To Buy Now?
Will IMAC Holdings, Inc. (IMAC) Report Negative Q2 Earnings? What You Should Know
IMAC Holdings, Inc. (IMAC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IMAC Holdings to Present at the Summer Solstice - Best Ideas from the Buy Side Conference on Tuesday, June 1, 2021
Brentwood, Tenn, May 26, 2021 (GLOBE NEWSWIRE) -- IMAC Holdin gs, Inc. (Nasdaq: IMAC, IMACW), a provider of innovative medical advancements and care specializing in regenerative and rehabilitation orthopedic treatments without the use of surgery or opioids, announced today that management has been invited to present at the Summer Solstice - Best Ideas from the Buy Side Conference, which is being held virtually on June 1 – June 4, 2021.
IMAC Holdings Announces Pricing of its Public Offering of Common Stock
Brentwood, Tenn, March 23, 2021 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (the “Company” or “IMAC”) (Nasdaq: IMAC, IMACW), a provider of innovative medical advancements and care specializing in regenerative and rehabilitation orthopedic treatments without the use of surgery or opioids, announced today the pricing of its underwritten registered public offering of 10,625,000 shares of its common stock at a public offering price of $1.60 per share, for total gross proceeds of $17.0 million. The net proceeds, after underwriting discounts, but before estimated expenses of the offering payable by IMAC, are expected to be approximately $16.0 million. All shares of common stock to be sold in the offering will be sold by the Company, except that the Company, together with its co-founder and chief operating officer as a selling stockholder, will grant the underwriter for the offering a 45-day option to purchase up to 15% of the shares of common stock in the offering. The offering is expected to close on or about March 26, 2021, subject to the satisfaction of customary closing conditions.
IMAC Holdings Reports 2020 Financial Results and Corporate Update
BRENTWOOD, Tenn., March 04, 2021 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or the “Company”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announced financial results for the year ended December 31, 2020.
IMAC Holdings, Inc. Announces Completion of First Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson's Disease
BRENTWOOD, Tenn, March 01, 2021 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or “the Company”), today announces it has completed the first cohort of its Phase 1 clinical trial for its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia due to Parkinson's disease.
IMAC Holdings Adds Regenerative Wound Care Service in Regeneration Centers
Insurance to Reimburse Services Providing Cell-Based Amniotic-Infused Mesh Application to Chronic Non-Healing Wounds and Diabetic Foot Ulcers
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
|Revenue per share||1.95||1.16||1.3|
|Net income per share||-0.84||-0.5||-0.95|
|Operating cash flow per share||-0.52||-0.54||-0.69|
|Free cash flow per share||-0.68||-0.55||-0.75|
|Cash per share||0.05||0.24||0.64|
|Book value per share||1.29||0.94||1.62|
|Tangible book value per share||-0.16||-0.49||0.68|
|Share holders equity per share||1.29||0.94||1.62|
|Interest debt per share||0.72||0.38||0.58|
|Price to sales ratio||0.6||1.45||1|
|EV to sales||0.89||1.52||0.91|
|Enterprise value over EBITDA||-3.32||-6.01||-1.57|
|EV to operating cash flow||-3.3||-3.26||-1.73|
|EV to free cash flow||-2.55||-3.2||-1.59|
|Free cash flow yield||-0.58||-0.33||-0.58|
|Debt to equity||0.21||0||0.23|
|Debt to assets||0.61||0.79||0.34|
|Net debt to EBITDA||-1.06||-0.31||0.14|
|Sales general and administrative to revenue||1.06||0.36||0.45|
|Research and developement to revenue||0||0||0|
|Intangibles to total assets||0.45||0.57||0.38|
|Capex to operating cash flow||0.29||0.02||0.09|
|Capex to revenue||-0.08||-0.01||-0.05|
|Capex to depreciation||-0.77||-0.07||-0.42|
|Stock based compensation to revenue||0.03||0.03||0.04|
|Return on tangible assets||-0.58||-0.85||-0.63|
|Tangible asset value||-1.27M||-5.4M||7.49M|
|Net current asset value||-9.9M||-7.18M||-208.63K|
|Days sales outstanding||30.36||43.05||30.68|
|Days payables outstanding||418.07||0||0|
|Days of inventory on hand||0||0||0|
|Capex per share||-0.15||-0.01||-0.06|
Quarterly Fundamentals Overview
Last date of statement is 2022-03-31 for Q1
|Revenue per share||0.23||0.14||0.14||0.17||0.15|
|Net income per share||-0.15||-0.08||-0.07||-0.19||-0.12|
|Operating cash flow per share||-0.13||-0.1||-0.06||-0.07||-0.1|
|Free cash flow per share||-0.14||-0.11||-0.06||-0.08||-0.11|
|Cash per share||1.16||0.54||0.44||0.28||0.17|
|Book value per share||1.91||1.03||0.95||0.71||0.59|
|Tangible book value per share||1.04||0.54||0.44||0.3||0.19|
|Share holders equity per share||1.91||1.03||0.95||0.71||0.59|
|Interest debt per share||0.57||0.31||0.27||0.24||0.21|
|Price to sales ratio||7.24||14.37||10.75||6.61||6.7|
|EV to sales||4.61||12.68||9.46||6.33||6.98|
|Enterprise value over EBITDA||-10.14||-30.78||-28.39||-6.27||-10.03|
|EV to operating cash flow||-8.06||-17.03||-23.38||-14.95||-11.13|
|EV to free cash flow||-7.54||-15.88||-21.4||-13.13||-10.21|
|Free cash flow yield||-0.08||-0.06||-0.04||-0.07||-0.1|
|Debt to equity||0.15||0.17||0.17||0.23||0.25|
|Debt to assets||0.32||0.31||0.33||0.34||0.38|
|Net debt to EBITDA||5.81||4.08||3.87||0.28||-0.41|
|Sales general and administrative to revenue||1.33||1.38||1.48||-1.74||0.47|
|Research and developement to revenue||0||0||0||0||0|
|Intangibles to total assets||0.26||0.27||0.29||0.38||0.42|
|Capex to operating cash flow||0.07||0.07||0.09||0.14||0.09|
|Capex to revenue||-0.04||-0.05||-0.04||-0.06||-0.06|
|Capex to depreciation||-0.29||-0.42||-0.29||-0.77||-0.49|
|Stock based compensation to revenue||0.04||0.04||0.05||0.03||0.05|
|Return on tangible assets||-0.08||-0.08||-0.08||-0.29||-0.23|
|Tangible asset value||13.97M||13.62M||11.02M||7.49M||4.76M|
|Net current asset value||7.5M||6.11M||3.91M||-208.63K||-2.55M|
|Days sales outstanding||54.22||34.81||29.82||24.91||39.86|
|Days payables outstanding||0||0||0||0||73.2|
|Days of inventory on hand||0||0||0||0||0|
|Capex per share||-0.01||-0.01||-0.01||-0.01||-0.01|
Frequently Asked Questions
What is IMAC Holdings, Inc. stock symbol ?
IMAC Holdings, Inc. is a US stock , located in Brentwood of Tennessee and trading under the symbol IMAC
What is IMAC Holdings, Inc. stock quote today ?
IMAC Holdings, Inc. stock price is $0.379 today.
Is IMAC Holdings, Inc. stock public?
Yes, IMAC Holdings, Inc. is a publicly traded company.